Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
|Articles|November 2, 2013
- Pharmaceutical Technology-11-02-2013
- Volume 37
- Issue 11
Database Improves Process Efficiency
Database Improves Process Efficiency
With the new version 10.1 of the Comos software solution, Siemens expands its range of industrial software for the process industry in plant engineering and plant management. The Comos Enterprise Platform for efficient and system-wide cooperation was developed using the new Comos industrial database (Comos iDB) which is designed for sector-specific requirements in a variety of industries. New projects can be installed quickly and easily, because fewer customer-specific adaptations are required. The Comos Enterprise Platform ensures fast data processing and secure data management even with an increasing volume of project data, the company reports.
Articles in this issue
almost 13 years ago
Report from Brazil November 2013almost 13 years ago
Applying Catalysis to Optimize API Synthesisalmost 13 years ago
Predicting Long-Term Storage Stability of Therapeutic Proteinsalmost 13 years ago
Control of Elemental Impuritiesalmost 13 years ago
Automation System Improves Operational Insightalmost 13 years ago
Disposable Applications in Demand by Biopharmaalmost 13 years ago
Solvent-Free Coating of Traditional and User-Friendly Dosage Formsalmost 13 years ago
Congress Revises Rules for Drug Compounding and Supply-Chain Securityalmost 13 years ago
Can Pharma Defy Gravity at the Patent Cliff?almost 13 years ago
Defining and Presenting Overkill Cycle ValidationRelated to this article
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.